Health News Roundup: Gilead cell therapy proves durable for some lymphoma patients; Yemen sterilizes Sanaa water supplies

Following is a summary of current health news briefs.

High-cost Gilead cell therapy proves durable for some lymphoma patients

Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc's Yescarta were still responding to the cell therapy after at least two years of follow-up, the company said on Sunday. The question of how long patients will benefit from Yescarta and other therapies in an expensive new class known as chimeric antigen receptor T-cell therapies, or CAR-Ts, has been a key topic at the annual meeting of the American Society of Hematology (ASH) in San Diego.

Yemen sterilizes Sanaa water supplies as cholera outbreak picks up again

Authorities in the Houthi-held Yemeni capital Sanaa are sterilizing water supplies at wells, distribution networks and houses to help stem the world's worst outbreak of cholera. Nearly four years of war between a Saudi-led coalition and the Iranian-aligned Houthi group have crippled healthcare and sanitation systems in Yemen, where some 1.2 million suspected cholera cases have been reported since 2017, with 2,515 deaths.

(With inputs from Reuters)